February 2, 2021 -- Private equity firm Welsh, Carson, Anderson & Stowe will commit up to $250 million in a strategic partnership with Kiniciti, a newly formed platform that will invest in nontherapeutic companies supporting innovation in cell and gene therapy.
The investment will focus on the following areas:
- Transformational capabilities in cell engineering and gene editing
- Value-added starting materials, including cell sourcing
- Process science and scale-up tools and services
- Production technologies
- Source-to-patient delivery
Kiniciti intends to invest in cell and gene therapy opportunities in a range of sizes and locations. Its strategy rests upon a flexible investment model to ensure companies supporting cell and gene customers have access to the resources needed to rapidly advance therapies.
The Kiniciti leadership team includes CEO Geoffrey Glass and chief strategy officer Jason Conner. Glass has more than 25 years of experience leading life sciences services and therapeutic companies. Conner has held senior strategy, corporate development, and leadership roles in multiple life sciences and services firms.
Copyright © 2021 scienceboard.net